A House panel responsible for advancing and monitoring the nation’s health care and research laws Thursday examined new bipartisan legislation supporting treatment and therapies derived from adult stem cell lines.
Rep. Chris Smith (NJ-04), author of the Stem Cell Therapeutic and Research Reauthorization Act of 2015 ( HR 2820), said he was encouraged that the Energy and Commerce Subcommittee on Health moved quickly to include the legislation in their hearing entitled: “Examining Public Health Legislation: H.R. 2820, H.R. 1344, and H.R. 1462.” Smith and Rep. Doris Matsui (D-Ca.) introduced the bill only last week with a bipartisan group of lawmakers.
“This important bipartisan legislation will save more lives,” said Smith who also authored the first law (The Stem Cell Therapeutic and Research Act of 2005—P.L. 109-129) creating the National Cord Blood Inventory (NCBI) program and continuing the C.W. Bill Young Cell Transplantation program. Smith said “The adult stem cells found in bone marrow and cord blood provide hope not only for curing the diseases and conditions currently known, but they also set the stage for even more cures in the future.”
Click here for the originiating article from National Right to Life.